Table 2 Clinical pathological features of sox signature genes in three cohorts
|  | TCGA LIHC Cohort I (n = 188) | TCGA LIHC Cohort II (n = 189) | LIRI-JP Cohort (n = 231) | ||||||
|---|---|---|---|---|---|---|---|---|---|
Low sox group | High sox group | P value | Low sox group | High sox group | P value | Low sox group | High sox group | P value | |
Gender | Â | Â | 0.020 | Â | Â | 0.014 | Â | Â | 0.671 |
 Male | 104 (55.3%) | 28 (14.9%) |  | 100 (52.9%) | 23 (12.2%) |  | 141 (61.0%) | 30 (13.0%) |  |
 Female | 35 (18.6%) | 21 (11.2%) |  | 43 (22.8%) | 23 (12.2%) |  | 48 (20.8%) | 12 (5.2%) |  |
Tumor Stage | Â | Â | 0.001 | Â | Â | 0.009 | Â | Â | 0.055 |
 I | 70 (37.2%) | 11 (5.9%) |  | 80 (42.3%) | 14 (7.4%) |  | 31 (13.4%) | 4 (1.7%) |  |
 II | 33 (17.6%) | 18 (9.6%) |  | 28 (14.8%) | 8 (4.2%) |  | 91 (39.4%) | 15 (6.5%) |  |
 III | 24 (12.8%) | 19 (10.1%) |  | 26 (13.8%) | 18 (9.5%) |  | 55 (23.8%) | 16 (6.9%) |  |
 IV | 1 (0.5%) | 0 (0%) |  | 2 (1.1%) | 1 (0.5%) |  | 12 (5.2%) | 7 (3.1%) |  |
Tumor Grade | Â | Â | 0.026 | Â | Â | 0.126 | Â | Â | NA |
 G1 | 32 (17.0%) | 2 (1.1%) |  | 18 (9.5%) | 3 (16.7%) |  | NA | NA |  |
 G2 | 62 (33.0%) | 27 (14.4%) |  | 73 (38.6%) | 18 (9.5%) |  | NA | NA |  |
 G3 | 37 (19.7%) | 19 (10.1%) |  | 45 (23.8%) | 23 (12.2%) |  | NA | NA |  |
 G4 | 6 (3.2%) | 1 (0.5%) |  | 5 (2.6%) | 1 (0.5%) |  | NA | NA |  |
Vascular Invasion | Â | Â | 0.003 | Â | Â | 0.001 | Â | Â | NA |
Macro | 3 (1.6%) | 2 (1.1%) | Â | 4 (2.1%) | 8 (4.2%) | Â | NA | NA | Â |
Micro | 41 (21.8%) | 19 (10.1%) | Â | 27 (14.3%) | 7 (3.7%) | Â | NA | NA | Â |
None | 79 (42.0%) | 14 (7.4%) | Â | 96 (50.8%) | 21 (11.1%) | Â | NA | NA | Â |